» Articles » PMID: 20050670

Rational Design of Targeted Cancer Therapeutics Through the Multiconjugation of Folate and Cleavable SiRNA to RAFT-synthesized (HPMA-s-APMA) Copolymers

Overview
Date 2010 Jan 7
PMID 20050670
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

A well-defined N-(2-hydroxypropyl)methacrylamide-s-N-(3-aminopropyl)methacrylamide (HPMA-s-APMA) copolymer, synthesized via reversible addition-fragmentation chain transfer (RAFT) polymerization, was utilized for the rational design of multiconjugates containing both a gene therapeutic, small interfering RNA (siRNA), and a cancer cell targeting moiety, folate. The copolymer contains a biocompatible poly(HPMA) portion (91 mol %) and a primary amine, APMA, portion (9 mol %). A fraction (20 mol %) of the APMA repeats were converted to activated thiols utilizing the amine- and sulfhydryl-reactive molecule N-succinimidyl 3-(2-pyridyldithio)-propionate (SPDP). 5'-Thiolated sense strand RNAs were then coupled to the polymer through a disulfide exchange with pendant pyridyldithio moieties, giving an 89 +/- 4% degree of conjugation. The unmodified APMA units (80 mol %) were subsequently coupled to amine reactive folates with 81 +/- 1% efficiency. This yielded a multiconjugate copolymer with 91 mol % HPMA, 2 mol % RNA, and 6 mol % folate. siRNA formation was achieved by annealing antisense strands to the conjugated RNA sense strands. Subsequent siRNA cleavage under intracellular conditions demonstrated the potential utility of this carrier in gene delivery. The multiconjugate copolymer and siRNA release were characterized by UV-vis spectroscopy and polyacrylamide gel electrophoresis.

Citing Articles

Beyond Lipids: Exploring Advances in Polymeric Gene Delivery in the Lipid Nanoparticles Era.

Jogdeo C, Siddhanta K, Das A, Ding L, Panja S, Kumari N Adv Mater. 2024; 36(31):e2404608.

PMID: 38842816 PMC: 11384239. DOI: 10.1002/adma.202404608.


Covalent Polymer-RNA Conjugates for Potent Activation of the RIG-I Pathway.

Palmer C, Pastora L, Kimmel B, Pagendarm H, Kwiatkowski A, Stone P Adv Healthc Mater. 2024; 14(5):e2303815.

PMID: 38648653 PMC: 11493851. DOI: 10.1002/adhm.202303815.


Enhanced control of bioactivity of tissue plasminogen activator (tPA) through domain-directed enzymatic oxidation of terminal galactose.

Mahdi W, Absar M, Choi S, Yang V, Kwon Y Bioimpacts. 2023; 12(6):479-486.

PMID: 36644546 PMC: 9809136. DOI: 10.34172/bi.2022.23477.


Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors.

Stickdorn J, Stein L, Arnold-Schild D, Hahlbrock J, Medina-Montano C, Bartneck J ACS Nano. 2022; 16(3):4426-4443.

PMID: 35103463 PMC: 8945363. DOI: 10.1021/acsnano.1c10709.


Thiolated-Polymer-Based Nanoparticles as an Avant-Garde Approach for Anticancer Therapies-Reviewing Thiomers from Chitosan and Hyaluronic Acid.

Grosso R, de-Paz M Pharmaceutics. 2021; 13(6).

PMID: 34201403 PMC: 8227107. DOI: 10.3390/pharmaceutics13060854.


References
1.
Boyer C, Bulmus V, Davis T . Efficient usage of thiocarbonates for both the production and the biofunctionalization of polymers. Macromol Rapid Commun. 2011; 30(7):493-7. DOI: 10.1002/marc.200800708. View

2.
Jia Z, Wong L, Davis T, Bulmus V . One-pot conversion of RAFT-generated multifunctional block copolymers of HPMA to doxorubicin conjugated acid- and reductant-sensitive crosslinked micelles. Biomacromolecules. 2008; 9(11):3106-13. DOI: 10.1021/bm800657e. View

3.
Braasch D, Jensen S, Liu Y, Kaur K, Arar K, White M . RNA interference in mammalian cells by chemically-modified RNA. Biochemistry. 2003; 42(26):7967-75. DOI: 10.1021/bi0343774. View

4.
Ulbrich K, Subr V . Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev. 2004; 56(7):1023-50. DOI: 10.1016/j.addr.2003.10.040. View

5.
Jeong J, Mok H, Oh Y, Park T . siRNA conjugate delivery systems. Bioconjug Chem. 2008; 20(1):5-14. DOI: 10.1021/bc800278e. View